"10.1371_journal.pone.0041865","plos one","2012-07-27T00:00:00Z","Nabil G Seidah; Steve Poirier; Maxime Denis; Rex Parker; Bowman Miao; Claudio Mapelli; Annik Prat; Hanny Wassef; Jean Davignon; Katherine A Hajjar; Gaétan Mayer","Laboratory of Molecular Cell Biology, Montreal Heart Institute, Département de Médecine and Département de Pharmacologie, Université de Montréal, Montréal, Québec, Canada; Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Affiliated to the Université de Montréal, Montréal, Québec, Canada; Hyperlipidemia and Atherosclerosis, Clinical Research Institute of Montreal, Affiliated to the Université de Montréal, Montréal, Québec, Canada; Bristol-Myers Squibb Pharmaceutical R & D, Princeton, New Jersey, United States of America; Department of Cell and Developmental Biology, Weill Cornell Medical College, Cornell University, New York, New York, United States of America","Conceived and designed the experiments: NGS SP RP BM CM HW GM. Performed the experiments: SP MD RP BM CM KAH GM. Analyzed the data: NGS SP RP BM CM GM. Contributed reagents/materials/analysis tools: JD HW CM RP AP BM KAH. Wrote the paper: NGS RP KAH MD HW SP GM.","The authors have read the journals policy and have the following conflicts: NGS, SP, MD, HW, JD, AP, are employees of the IRCM. GM is an employee of MHI. KAH is an employee of Cornell University. RP, BM and CM are employees of Bristol-Myers Squibb. GM, SP, NGS and IRCM have a patent on the inhibition of PCSK9 by Annexin A2 and derivatives thereof (#12/994,835). This does not alter the authors adherence to all the PLOS ONE policies, including sharing data and materials.","2012","07","Nabil G Seidah","NGS",11,TRUE,7,7,6,7,TRUE,TRUE,FALSE,0,NA,FALSE
